US4210478A
(en)
*
|
1973-05-08 |
1980-07-01 |
International Paper Company |
Method of making a catheter
|
US3959429A
(en)
*
|
1975-02-03 |
1976-05-25 |
International Paper Company |
Method of making a retention catheter and molding a tip thereon
|
US3985601A
(en)
*
|
1975-05-05 |
1976-10-12 |
Quantum, Inc. |
Method for producing a balloon type catheter having a smooth continuous outer surface
|
US4361152A
(en)
*
|
1975-05-27 |
1982-11-30 |
The Kendall Company |
Catheter
|
US4188954A
(en)
*
|
1976-08-05 |
1980-02-19 |
The Kendall Company |
Catheter with improved balloon assembly
|
US4082114A
(en)
*
|
1977-01-28 |
1978-04-04 |
The Trane Company |
Valve assembly for use in an air distribution system
|
US4168710A
(en)
*
|
1977-08-10 |
1979-09-25 |
The Kendall Company |
Balloon cuff and catheter assembly
|
US4143651A
(en)
*
|
1977-11-03 |
1979-03-13 |
The Kendall Company |
Catheter
|
US4222384A
(en)
*
|
1977-11-09 |
1980-09-16 |
Biomedical Engineering Associates, Inc. |
Catheter
|
JPS552348U
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
*
|
1978-06-21 |
1980-01-09 |
|
|
US4284459A
(en)
*
|
1978-07-03 |
1981-08-18 |
The Kendall Company |
Method for making a molded catheter
|
US4251305A
(en)
*
|
1978-11-01 |
1981-02-17 |
Baxter Travenol Laboratories, Inc. |
Method of radiant heat sealing of a balloon onto a catheter employing tinted shrink tubing
|
JPS56152655A
(en)
*
|
1980-04-28 |
1981-11-26 |
Terumo Corp |
Balloon catheter with backward flow preventing valve
|
US4445891A
(en)
*
|
1980-05-05 |
1984-05-01 |
The Kendall Company |
Catheter
|
US4445890A
(en)
*
|
1980-05-05 |
1984-05-01 |
The Kendall Company |
Catheter
|
US4447228A
(en)
*
|
1980-05-05 |
1984-05-08 |
The Kendall Company |
Catheter
|
FR2513566A1
(fr)
*
|
1981-09-29 |
1983-04-01 |
Matburn Holdings Ltd |
Procede pour fixer ensemble les matieres plastiques et le caoutchouc
|
FR2521014B1
(fr)
*
|
1982-02-05 |
1988-06-03 |
Matburn Holdings Ltd |
Instrument chirurgical tubulaire, notamment catheter de thrombectomie
|
DE3438131C2
(de)
*
|
1984-10-18 |
1986-08-21 |
Werner Dr.med. 4330 Mülheim Schubert |
Vorrichtung zur Beseitigung von Konkrementen
|
US4787892A
(en)
*
|
1984-12-18 |
1988-11-29 |
The Kendall Company |
Nephrostomy catheter with formed tip
|
US4636272A
(en)
*
|
1985-02-19 |
1987-01-13 |
Cordis Corporation |
Process for thermally bonding plastic tubes
|
US4782834A
(en)
*
|
1987-01-06 |
1988-11-08 |
Advanced Cardiovascular Systems, Inc. |
Dual lumen dilatation catheter and method of manufacturing the same
|
US4861337A
(en)
*
|
1988-03-02 |
1989-08-29 |
Sherwood Medical Company |
Collapsible urethral catheter
|
US5095915A
(en)
*
|
1990-03-19 |
1992-03-17 |
Target Therapeutics |
Guidewire with flexible distal tip
|
JP2502174B2
(ja)
*
|
1990-08-07 |
1996-05-29 |
富士システムズ株式会社 |
バル―ンカテ―テルの製造方法
|
US5257451A
(en)
*
|
1991-11-08 |
1993-11-02 |
Ep Technologies, Inc. |
Method of making durable sleeve for enclosing a bendable electrode tip assembly
|
US5460608A
(en)
*
|
1994-01-25 |
1995-10-24 |
Scimed Life Systems, Inc. |
Kink free catheter
|
SE9404486D0
(sv)
*
|
1994-12-22 |
1994-12-22 |
Astra Ab |
Catheter
|
US5527281A
(en)
*
|
1995-07-27 |
1996-06-18 |
Haas; Joseph A. |
Substitute tip for urethral catheter
|
SE9600276D0
(sv)
|
1996-01-25 |
1996-01-25 |
Astra Ab |
A wetting device for wetting a hydrophilic catheter and a urine collection bag incorporating said device
|
US5965532A
(en)
*
|
1996-06-28 |
1999-10-12 |
Trustees Of Tufts College |
Multivalent compounds for crosslinking receptors and uses thereof
|
ES2374621T3
(es)
|
1997-04-02 |
2012-02-20 |
The Brigham And Women's Hospital, Inc. |
Medios para evaluar el perfil de riesgo de un individuo de sufrir una enfermedad ateroesclerótica.
|
EP1096952B1
(en)
|
1998-07-15 |
2008-05-21 |
The Brigham And Women's Hospital, Inc. |
Polysaccharide vaccine for staphylococcal infections
|
US6368301B1
(en)
*
|
1999-12-21 |
2002-04-09 |
Advanced Cardiovascular Systems, Inc. |
Catheter having a soft distal tip
|
AU4351201A
(en)
|
2000-03-08 |
2001-09-17 |
Massachusetts Inst Technology |
Heparinase iii and uses thereof
|
WO2001078709A2
(en)
*
|
2000-04-12 |
2001-10-25 |
Minerva Biotechnologies Corporation |
Treatment of neurodegenerative disease
|
KR100434720B1
(ko)
*
|
2001-01-03 |
2004-06-07 |
이근호 |
발룬 카테테르의 제조방법
|
US6692461B2
(en)
|
2001-08-07 |
2004-02-17 |
Advanced Cardiovascular Systems, Inc. |
Catheter tip
|
US6918920B1
(en)
*
|
2001-11-01 |
2005-07-19 |
Advanced Cardiovascular Systems, Inc. |
Catheter having an improved distal tip
|
AU2003225724A1
(en)
*
|
2002-03-11 |
2003-09-29 |
Momenta Pharmaceuticals, Inc. |
Analysis of sulfated polysaccharides
|
EP1483283A4
(en)
|
2002-03-13 |
2007-04-11 |
Signum Biosciences Inc |
MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE
|
US7344505B2
(en)
*
|
2002-10-15 |
2008-03-18 |
Transoma Medical, Inc. |
Barriers and methods for pressure measurement catheters
|
FI1897548T4
(fi)
|
2003-02-28 |
2024-09-03 |
The Johns Hopkins University |
T-solujen säätely
|
EP2377528B1
(en)
|
2003-06-12 |
2014-02-19 |
The Board of Regents of the University of Colorado |
Fatty acid metabolism inhibitors for use in the treatment of cancer
|
CA2535971C
(en)
|
2003-08-20 |
2018-04-10 |
Biosite, Inc. |
Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
|
US7655000B2
(en)
*
|
2003-09-26 |
2010-02-02 |
Tyco Healthcare Group Lp |
Urology catheter
|
US7972350B2
(en)
*
|
2004-01-29 |
2011-07-05 |
Boston Scientific Scimed, Inc. |
Catheter tip
|
JP5230865B2
(ja)
|
2004-07-15 |
2013-07-10 |
テトラロジック ファーマシューティカルズ コーポレーション |
Iap結合性化合物
|
JP5070052B2
(ja)
|
2004-08-17 |
2012-11-07 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
Pde5阻害剤組成物及び心臓疾患を治療する方法
|
CA2583375C
(en)
|
2004-09-02 |
2013-01-15 |
Yale University |
Regulation of oncogenes by micrornas
|
WO2006034454A1
(en)
*
|
2004-09-23 |
2006-03-30 |
The Trustees Of The University Of Princeton |
Bcl-2 family member and bh-3 only proteins for use in development of peptidomimetics
|
WO2006042192A2
(en)
|
2004-10-06 |
2006-04-20 |
The Brigham And Womens's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
WO2006052940A2
(en)
*
|
2004-11-05 |
2006-05-18 |
Asthmatx, Inc. |
Medical device with procedure improvement features
|
CA2601777A1
(en)
|
2005-02-03 |
2006-08-10 |
Signum Biosciences, Inc. |
Compositions and methods for enhancing cognitive function
|
US7923041B2
(en)
|
2005-02-03 |
2011-04-12 |
Signum Biosciences, Inc. |
Compositions and methods for enhancing cognitive function
|
US8841259B2
(en)
*
|
2005-02-24 |
2014-09-23 |
Joslin Diabetes Center |
Compositions and methods for treating vascular permeability
|
EP2385038A1
(en)
|
2005-02-25 |
2011-11-09 |
Tetralogic Pharmaceuticals Corporation |
Dimeric IAP inhibitors
|
US8354384B2
(en)
*
|
2005-06-23 |
2013-01-15 |
Yale University |
Anti-aging micrornas
|
EP1906972B1
(en)
|
2005-07-19 |
2013-09-11 |
The University of Tennessee Research Foundation |
LPA2 receptor agonist for treating diarrhea
|
CA2616537A1
(en)
|
2005-07-27 |
2007-02-01 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
AU2006279929A1
(en)
*
|
2005-08-09 |
2007-02-22 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
US20080021198A1
(en)
*
|
2005-10-12 |
2008-01-24 |
Yigong Shi |
Modulators of protein phosphatase 2A and PP2A methyl esterase
|
US8658608B2
(en)
*
|
2005-11-23 |
2014-02-25 |
Yale University |
Modified triple-helix forming oligonucleotides for targeted mutagenesis
|
AU2006320327A1
(en)
*
|
2005-12-01 |
2007-06-07 |
Duke University |
Compounds and methods for inhibiting apoptosis
|
AU2007276760B2
(en)
*
|
2006-07-24 |
2012-01-19 |
Tetralogic Pharmaceuticals Corporation |
Dimeric IAP antagonists
|
US20100056495A1
(en)
*
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
WO2008014240A2
(en)
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
US20100143499A1
(en)
*
|
2006-07-24 |
2010-06-10 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
AR064235A1
(es)
*
|
2006-07-24 |
2009-03-25 |
Tetralogic Pharmaceuticals Cor |
Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
|
US20080153773A1
(en)
*
|
2006-08-08 |
2008-06-26 |
Yigong Shi |
Modulators of phosphotyrosyl phosphatase activator
|
US20100092480A1
(en)
*
|
2006-10-13 |
2010-04-15 |
The Trustees Of The University Of Princeton |
Modulators of protein phosphatase 2a
|
US7645616B2
(en)
*
|
2006-10-20 |
2010-01-12 |
The University Of Hong Kong |
Use of lipocalin-2 as a diagnostic marker and therapeutic target
|
AU2008205410B2
(en)
|
2007-01-05 |
2013-10-10 |
Massachusetts Institute Of Technology |
Compositions of and methods of using sulfatases from flavobacterium heparinum
|
EP2099911A2
(en)
*
|
2007-01-11 |
2009-09-16 |
Yale University |
Compositions and methods for targeted inactivation of hiv cell surface receptors
|
US20100119474A1
(en)
*
|
2007-03-06 |
2010-05-13 |
Cornell University |
Chronic obstructive pulmonary disease susceptibility and related compositions and methods
|
WO2008116216A1
(en)
*
|
2007-03-22 |
2008-09-25 |
Medical College Of Georgia Research Institute, Inc. |
Compositions and methods for inhibiting cancer metastasis
|
WO2008122039A2
(en)
*
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
US9139876B1
(en)
|
2007-05-03 |
2015-09-22 |
Momenta Pharmacueticals, Inc. |
Method of analyzing a preparation of a low molecular weight heparin
|
EP2559772B1
(en)
|
2007-06-08 |
2015-04-15 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Methods for determining a hepatocellular carcinoma subtype
|
US20090274682A1
(en)
*
|
2008-02-05 |
2009-11-05 |
The Trustees Of Princeton University |
Demethylation and inactivation of protein phosphatase 2a
|
WO2009108745A1
(en)
*
|
2008-02-26 |
2009-09-03 |
The Trustees Of Princeton University |
Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
|
WO2009137660A2
(en)
*
|
2008-05-07 |
2009-11-12 |
Abraxis Bioscience, Llc |
Enhancement of drug therapy by mirna
|
US20100146875A1
(en)
*
|
2008-05-30 |
2010-06-17 |
John Redding |
Support post structure
|
US9273136B2
(en)
*
|
2008-08-04 |
2016-03-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human anti-human NKG2D monoclonal antibodies
|
AU2009293403A1
(en)
|
2008-09-17 |
2010-03-25 |
Tetralogic Pharmaceuticals Corp. |
IAP inhibitors
|
EP2331103A1
(en)
*
|
2008-09-22 |
2011-06-15 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Nuclear factor kappa b pathway inhibitor composition and use of same
|
WO2010075417A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Survivin specific t cell receptor for treating cancer
|
WO2010075303A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
|
US8309356B2
(en)
*
|
2009-04-01 |
2012-11-13 |
Yale University |
Pseudocomplementary oligonucleotides for targeted gene therapy
|
AU2010238723A1
(en)
|
2009-04-23 |
2011-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human ROR1 antibodies
|
EP3375441A1
(en)
|
2009-04-30 |
2018-09-19 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Schweinfurthins and uses thereof
|
US8877199B2
(en)
|
2009-05-15 |
2014-11-04 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
B cell surface reactive antibodies
|
IN2012DN00352A
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
WO2011011797A2
(en)
|
2009-07-24 |
2011-01-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Cytokine compositions and methods of use thereof
|
EP2287304A1
(en)
|
2009-08-17 |
2011-02-23 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
|
AU2010301042B2
(en)
|
2009-10-01 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
US8435795B2
(en)
*
|
2010-01-19 |
2013-05-07 |
Momenta Pharmaceuticals, Inc. |
Evaluating heparin preparations
|
WO2011133803A1
(en)
|
2010-04-21 |
2011-10-27 |
Helix Therapeutics, Inc. |
Compositions and methods for targeted inactivation of hiv cell surface receptors
|
US20110293585A1
(en)
|
2010-04-21 |
2011-12-01 |
Helix Therapeutics, Inc. |
Compositions and methods for treatment of lysosomal storage disorders
|
WO2012012627A1
(en)
|
2010-07-22 |
2012-01-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of preventing or treating viral infection
|
EP2646469B1
(en)
|
2010-12-01 |
2017-11-01 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Chimeric rabbit/human ror1 antibodies
|
EP2670850B1
(en)
|
2011-02-03 |
2016-10-26 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-34
|
MX2013008944A
(es)
|
2011-02-03 |
2014-01-08 |
Mirna Therapeutics Inc |
Mimeticos sinteticos de mir-124.
|
US9068957B2
(en)
|
2011-02-21 |
2015-06-30 |
Momenta Pharmaceuticals, Inc. |
Evaluating heparin preparations
|
WO2012125623A2
(en)
|
2011-03-14 |
2012-09-20 |
Ludwig Institute For Cancer Research Ltd. |
Cleavage inhibitors of transforming growth factor beta type i receptor and uses thereof in cancer therapy
|
EP3459560B1
(en)
|
2011-04-08 |
2021-02-24 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
US20140287043A1
(en)
|
2011-04-21 |
2014-09-25 |
Trustees Of Tufts College |
Compositions and methods for stabilization of active agents
|
CN106431988A
(zh)
|
2011-06-14 |
2017-02-22 |
比卡姆药品公司 |
视蛋白结合配体、组合物及使用方法
|
CA2842321C
(en)
|
2011-07-18 |
2022-05-03 |
President And Fellows Of Harvard College |
Engineered microbe-targeting molecules and uses thereof
|
EP2739734A1
(en)
|
2011-08-03 |
2014-06-11 |
The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System |
Treatment of fibrosis using microrna-19b
|
WO2013058809A1
(en)
|
2011-10-19 |
2013-04-25 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
ES2654060T3
(es)
|
2011-10-20 |
2018-02-12 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Receptores de antígenos quiméricos anti-CD22
|
JP6126118B2
(ja)
|
2011-11-30 |
2017-05-10 |
ビカム ファーマスーティカルス,インコーポレイテッド |
オプシン結合性リガンド、組成物、及び使用方法
|
CA2862746A1
(en)
|
2011-12-01 |
2013-06-06 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
CA3209571A1
(en)
|
2012-03-23 |
2013-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
US10076535B2
(en)
|
2012-04-27 |
2018-09-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing
|
CN110511278B
(zh)
|
2012-05-07 |
2024-08-09 |
达特茅斯大学理事会 |
抗b7-h6抗体、融合蛋白及其使用方法
|
US9119858B2
(en)
|
2012-08-21 |
2015-09-01 |
Genesys Research Institute, Inc. |
Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
|
ES2718903T3
(es)
|
2012-10-24 |
2019-07-05 |
Us Health |
Receptores de antígenos quiméricos M971
|
US9872851B2
(en)
|
2012-12-12 |
2018-01-23 |
The Charlotte-Mecklenburg Hospital Authority |
Methods of treating portal hypertension
|
WO2014093711A1
(en)
|
2012-12-12 |
2014-06-19 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System |
Methods of treating hepatic fibrosis and associated diseases by regulating rev-erb activity
|
ES3007461T3
(en)
|
2013-03-14 |
2025-03-20 |
Childrens Medical Center |
Use of cd36 to identify cancer subjects for treatment by a psap peptide
|
US11376329B2
(en)
|
2013-03-15 |
2022-07-05 |
Trustees Of Tufts College |
Low molecular weight silk compositions and stabilizing silk compositions
|
KR20210149207A
(ko)
|
2013-03-15 |
2021-12-08 |
트러스티즈 오브 터프츠 칼리지 |
저분자량 실크 조성물 및 안정화 실크 조성물
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
WO2014162007A2
(en)
|
2013-04-04 |
2014-10-09 |
Ieo - Istituto Europeo Di Oncologia Srl |
Thymic stromal lymphopoietin fragments and uses thereof
|
US10274503B2
(en)
|
2013-05-08 |
2019-04-30 |
Vegenics Pty Limited |
Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
|
KR20160030099A
(ko)
|
2013-06-25 |
2016-03-16 |
더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 |
세포내 감염의 치료 방법
|
WO2015006543A1
(en)
|
2013-07-10 |
2015-01-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method for predicting and detecting tumor metastasis in kidney cancer
|
CA2928135A1
(en)
|
2013-10-21 |
2015-04-30 |
Salk Institute For Biological Studies |
Mutated fibroblast growth factor (fgf) 1 and methods of use
|
US10676528B2
(en)
|
2013-12-06 |
2020-06-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
US10513546B2
(en)
|
2013-12-18 |
2019-12-24 |
President And Fellows Of Harvard College |
CRP capture/detection of gram positive bacteria
|
CA2943802A1
(en)
|
2014-03-26 |
2015-10-01 |
Children's Medical Center Corporation |
Cyclic prosaposin peptides and uses thereof
|
EP3139909B1
(en)
|
2014-05-09 |
2025-01-01 |
Yale University |
Hyperbranched polyglycerol-coated particles
|
US11918695B2
(en)
|
2014-05-09 |
2024-03-05 |
Yale University |
Topical formulation of hyperbranched polymer-coated particles
|
JP6613304B2
(ja)
|
2014-09-17 |
2019-12-04 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
抗cd276抗体(b7h3)
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
EP3270937A4
(en)
|
2015-03-26 |
2018-09-12 |
The Trustees Of Dartmouth College |
Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
|
KR20180033499A
(ko)
|
2015-06-05 |
2018-04-03 |
아이바이오, 인크. |
섬유증을 치료하는데 사용하기 위한 엔도스타틴 단편 및 변이체
|
EP3109257B1
(en)
|
2015-06-26 |
2021-01-06 |
Prindex S.r.l. |
Diagnosis and therapy of multiple sclerosis
|
US10973912B2
(en)
|
2015-06-29 |
2021-04-13 |
President And Fellows Of Harvard College |
Treatment for myopathy
|
US10435457B2
(en)
|
2015-08-06 |
2019-10-08 |
President And Fellows Of Harvard College |
Microbe-binding molecules and uses thereof
|
CN108848669B
(zh)
|
2016-01-20 |
2022-06-07 |
斯克利普斯研究所 |
Ror1抗体组合物和相关方法
|
WO2017127702A1
(en)
|
2016-01-20 |
2017-07-27 |
The Scripps Research Institute |
Ror2 antibody compositions and related methods
|
AU2017221405A1
(en)
|
2016-02-16 |
2018-09-20 |
Carnegie Mellon University |
Compositions for enhancing targeted gene editing and methods of use thereof
|
WO2017143061A1
(en)
|
2016-02-16 |
2017-08-24 |
Yale University |
Compositions and methods for treatment of cystic fibrosis
|
AU2017253935B2
(en)
|
2016-04-19 |
2021-07-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of gram negative species to treat atopic dermatitis
|
US10293005B2
(en)
|
2016-04-19 |
2019-05-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of gram negative species to treat atopic dermatitis
|
MX395142B
(es)
|
2016-05-16 |
2025-03-25 |
Checkmab S R L |
Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores.
|
EP4413999A3
(en)
|
2016-05-27 |
2024-08-28 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Flt3-specific chimeric antigen receptors and methods using same
|
WO2017207623A1
(en)
|
2016-05-31 |
2017-12-07 |
Université de Lausanne |
Mirna as biomarkers and regulators of cancer stem cells
|
WO2018005799A1
(en)
|
2016-06-29 |
2018-01-04 |
Georgia State University Research Foundation, Inc. |
Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
|
US20190201414A1
(en)
|
2016-07-01 |
2019-07-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
|
EP3595636A4
(en)
|
2017-03-16 |
2021-01-13 |
Children's Medical Center Corporation |
ENGINEERED LIPOSOMES USED AS THERAPEUTIC AGENTS TARGETING CANCER
|
US20200113821A1
(en)
|
2017-04-04 |
2020-04-16 |
Yale University |
Compositions and methods for in utero delivery
|
CA3061164A1
(en)
|
2017-04-25 |
2018-11-01 |
Prothera Biologics, Inc. |
Methods for quantifying inter-alpha inhibitor proteins
|
EP3655437A1
(en)
|
2017-07-20 |
2020-05-27 |
NBE-Therapeutics AG |
Human antibodies binding to ror2
|
AU2018315127B2
(en)
|
2017-08-07 |
2021-12-23 |
Nbe-Therapeutics Ag |
Anthracycline-based antibody drug conjugates having high in vivo tolerability
|
WO2019154884A1
(en)
|
2018-02-07 |
2019-08-15 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Method for determining cancer invasiveness and patient prognosis
|
US10973841B2
(en)
|
2018-05-11 |
2021-04-13 |
Forte Subsidiary, Inc. |
Compositions for the treatment of skin conditions
|
CA3114911A1
(en)
|
2018-10-04 |
2020-04-09 |
Rutgers, The State University Of New Jersey |
Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
|
US11266617B2
(en)
|
2018-10-16 |
2022-03-08 |
Massachusetts Institute Of Technology |
Beta-hydroxybutyrate encapsulated PLGA nanoparticle compositions
|
US20210340562A1
(en)
|
2018-10-19 |
2021-11-04 |
Board Of Regents, The University Of Texas System |
Engineered long interspersed element (line) transposons and methods of use
|
EP3677693A1
(en)
|
2019-01-03 |
2020-07-08 |
Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO |
Transpochimeric gene trancripts (tcgts) as cancer biomarkers
|
EP3911677A1
(en)
|
2019-01-18 |
2021-11-24 |
Janssen Biotech, Inc. |
Gprc5d chimeric antigen receptors and cells expressing the same
|
AU2020215177A1
(en)
|
2019-01-30 |
2021-08-12 |
Janssen Pharmaceutica Nv |
Methods of treating prostate cancer based on molecular subtypes
|
WO2020186187A1
(en)
|
2019-03-13 |
2020-09-17 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods for treating bladder and urethra dysfunction and disease
|
AU2020271123A1
(en)
|
2019-04-10 |
2021-11-25 |
Elevatebio Technologies, Inc. |
FLT3-specific chimeric antigen receptors and methods of using the same
|
CA3139032A1
(en)
|
2019-05-22 |
2020-11-26 |
Robert Alexander WESSELHOEFT |
Circular rna compositions and methods
|
WO2020239478A1
(en)
|
2019-05-28 |
2020-12-03 |
Pharma Mar, S.A. |
Trabectedin for treating sarcomas based on genomic markers
|
US20220243211A1
(en)
|
2019-06-21 |
2022-08-04 |
Yale University |
Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
|
US20220372474A1
(en)
|
2019-06-21 |
2022-11-24 |
Yale University |
Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
|
JOP20220018A1
(ar)
|
2019-07-26 |
2023-01-30 |
Janssen Biotech Inc |
مستقبل المستضدات الخيمري لـ hK2 المضاد (CAR)
|
AU2020322222A1
(en)
|
2019-07-26 |
2022-03-24 |
Janssen Biotech, Inc. |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
WO2021022161A1
(en)
|
2019-07-31 |
2021-02-04 |
Yale University |
Compositions and methods for treating sickle cell disease
|
CN112390894A
(zh)
|
2019-08-12 |
2021-02-23 |
广东东阳光药业有限公司 |
嵌合抗原受体及其应用
|
CN114761570A
(zh)
|
2019-08-16 |
2022-07-15 |
詹森生物科技公司 |
具有改善的功能的治疗性免疫细胞及其制备方法
|
JOP20220117A1
(ar)
|
2019-11-18 |
2023-01-30 |
Janssen Biotech Inc |
مستقبلات المستضدات الخيمرية المضادة لـ cd79 وخلايا car التائية واستخداماتهما
|
IL271778A
(en)
|
2019-12-31 |
2021-06-30 |
Ichilov Tech Ltd |
Methods for treating atopic dermatitis
|
EP3868396A1
(en)
|
2020-02-20 |
2021-08-25 |
Enthera S.R.L. |
Inhibitors and uses thereof
|
IL302351A
(en)
|
2020-03-13 |
2023-06-01 |
Janssen Biotech Inc |
Materials and methods for binding siglec-3/cd33
|
US20230181672A1
(en)
|
2020-05-07 |
2023-06-15 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
|
MX2022014660A
(es)
|
2020-05-19 |
2023-02-16 |
Orna Therapeutics Inc |
Composiciones y métodos de arn circular.
|
JP2023537470A
(ja)
|
2020-08-03 |
2023-09-01 |
ヤンセン バイオテツク,インコーポレーテツド |
ウイルス治療における多方向バイオ輸送のための材料及び方法
|
CN112295084B
(zh)
*
|
2020-09-25 |
2023-03-28 |
池州市琼琚信息技术服务有限公司 |
一种热收缩膜固定胶水形状的方法
|
JP2023554215A
(ja)
|
2020-10-16 |
2023-12-27 |
ユニバーシティー オブ ジョージア リサーチ ファウンデーション,インコーポレイテッド |
糖共役体
|
EP4059498A1
(en)
|
2021-03-16 |
2022-09-21 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Methods and compositions for treating conditions associated with hypermineralization
|
IL306103A
(en)
|
2021-03-24 |
2023-11-01 |
Janssen Biotech Inc |
The antibody targets CD22 and CD79B
|
WO2022237974A1
(en)
|
2021-05-12 |
2022-11-17 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Krab-containing zinc finger protein and cancer
|
CN115404240A
(zh)
|
2021-05-28 |
2022-11-29 |
上海环码生物医药有限公司 |
制备环形rna的构建体、方法及其用途
|
EP4352226A1
(en)
|
2021-06-07 |
2024-04-17 |
Yale University |
Peptide nucleic acids for spatiotemporal control of crispr-cas binding
|
WO2022271955A1
(en)
|
2021-06-23 |
2022-12-29 |
Musc Foundation For Research Development |
Novel targeted shrna nanoparticles for cancer therapy
|
KR20240049361A
(ko)
|
2021-08-25 |
2024-04-16 |
아이바이오, 인크. |
항-cd25 항체
|
US20250019455A1
(en)
|
2021-09-24 |
2025-01-16 |
Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
TW202334080A
(zh)
|
2021-11-08 |
2023-09-01 |
美商歐納醫療公司 |
用於遞送環狀聚核苷酸之脂質奈米粒子組合物
|
WO2023231959A2
(en)
|
2022-05-30 |
2023-12-07 |
Shanghai Circode Biomed Co., Ltd |
Synthetic circular rna compositions and methods of use thereof
|
US12297285B2
(en)
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
WO2024094526A1
(en)
|
2022-11-02 |
2024-05-10 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
6-diazo-5-oxo-l-norleucine prodrugs
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
AU2023398825A1
(en)
|
2022-12-15 |
2025-06-26 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
WO2024263649A1
(en)
|
2023-06-19 |
2024-12-26 |
Yale University |
Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
|
WO2025007148A1
(en)
|
2023-06-30 |
2025-01-02 |
Orna Therapeutics, Inc. |
Polymer lipid nanoparticle compositions for delivering circular polynucleotides
|
WO2025021993A1
(en)
|
2023-07-27 |
2025-01-30 |
Omnilinx Therapeutics Ag |
Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
EP4537907A1
(en)
|
2023-10-10 |
2025-04-16 |
Enthera S.r.l. |
Cd248 inhibitors and uses thereof
|
WO2025117969A1
(en)
|
2023-12-01 |
2025-06-05 |
Orna Therapeutics, Inc. |
Process for manufacturing lipid nanoparticles
|